Assessing the Predictive Value of JAK2 V617F Allele Burden in Non-CML Classical Subtypes of Myeloproliferative Neoplasms

被引：0
|
作者：
Gober-Wilcox, Julie [1 ]
Vennapusa, Bharathi [1 ]
Pierce, Joseph [2 ]
Vasef, Mohammad A. [1 ,2 ]
机构：
[1] Univ New Mexico, Dept Pathol, Albuquerque, NM 87131 USA
[2] TriCore Reference Lab, Albuquerque, NM USA
来源：
AMERICAN JOURNAL OF CLINICAL PATHOLOGY | 2009年 / 132卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
28
引用
收藏
页码：455 / 455
页数：1
相关论文
共 50 条
  • [31] IMPACT OF THE JAK2 (V617F) MUTATION AND THE MUTANT ALLELE BURDEN ON DISEASE PROGRESSION IN CHRONIC MYELOPROLIFERATIVE DISORDERS
    Passamonti, F.
    Rumi, E.
    Pietra, D.
    Boveri, E.
    Pascutto, C.
    Lazzarino, M.
    Cazzola, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 298 - 299
  • [32] Association of TNF polymorphisms with JAK2 (V617F) myeloproliferative neoplasms in Brazilian patients
    Macedo, Luciana Conci
    Quintero, Fernanda de Cesare
    Pagliari-E-Silva, Sara
    Barbosa Pagnano, Katia Borgia
    Rodrigues, Camila
    de Alencar, Josiane Bazzo
    Sell, Ana Maria
    Laguila Visentainer, Jeane Eliete
    BLOOD CELLS MOLECULES AND DISEASES, 2016, 57 : 54 - 57
  • [33] JAK2 V617F mutation detection in chronic myeloproliferative neoplasms by digital PCR
    Waterhouse, M.
    Pfeifer, D.
    Follo, M.
    Bertz, H.
    Finke, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 196 - 196
  • [34] A molecular diagnostic algorithm for JAK2 V617F investigations in suspected myeloproliferative neoplasms
    Mark Alexander Catherwood
    Roisin McAllister
    Patrick McCallion
    Julie Elizabeth McGimpsey
    Andrew Hindley
    John Feerick
    Greame Greenfield
    Paul Kennedy
    Gary Benson
    Claire Arnold
    Bridgin Merron
    Mary Frances McMullin
    Irish Journal of Medical Science (1971 -), 2020, 189 : 621 - 626
  • [35] Coexistence of lymphoproliferative and myeloproliferative neoplasms with simultaneous CALR and JAK2 V617F mutations
    Yang, Hai-Su
    CANCER BIOMARKERS, 2016, 17 (04) : 383 - 389
  • [36] A molecular diagnostic algorithm for JAK2 V617F investigations in suspected myeloproliferative neoplasms
    Catherwood, Mark Alexander
    McAllister, Roisin
    McCallion, Patrick
    McGimpsey, Julie Elizabeth
    Hindley, Andrew
    Feerick, John
    Greenfield, Greame
    Kennedy, Paul
    Benson, Gary
    Arnold, Claire
    Merron, Bridgin
    McMullin, Mary Frances
    IRISH JOURNAL OF MEDICAL SCIENCE, 2020, 189 (02) : 621 - 626
  • [37] JAK-STAT PATHWAY IN MYELOPROLIFERATIVE NEOPLASMS: FROM JAK2 V617F TO CALRETICULIN MUTANTS
    Constantinescu, S. N.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2017, 121 : 31 - 31
  • [38] TO TAKE HOME: HOW MUCH VALUE IS LOW BURDEN OF JAK2 V617F ALLELE MUTATION?
    Torres-Miana, L.
    Moreno, M.
    Cruz, N.
    Bilbao, C.
    Gonzalez, J.
    Santana, G.
    Gomez-Casares, T.
    Molero, T.
    HAEMATOLOGICA, 2015, 100 : 525 - 525
  • [39] Angiogenesis in JAK2 V617F positive myeloproliferative neoplasms and ruxolitinib decrease VEGF, HIF-1 enesis in JAK2 V617F positive cells
    Cheng, Zhiyong
    Fu, Jianzhu
    Liu, Guimin
    Zhang, Lijun
    Xu, Qian
    Wang, Su-yun
    LEUKEMIA & LYMPHOMA, 2018, 59 (01) : 196 - 203
  • [40] No evidence for amplification of V617F JAK2 in myeloproliferative disorders
    Jones, A. V.
    Bunyan, D. J.
    LEUKEMIA, 2007, 21 (12) : 2561 - 2563
12345